{"id":55513,"date":"2026-01-26T21:00:07","date_gmt":"2026-01-26T13:00:07","guid":{"rendered":"https:\/\/flcube.com\/?p=55513"},"modified":"2026-01-26T21:00:09","modified_gmt":"2026-01-26T13:00:09","slug":"merck-abandons-32-billion-revolution-medicines-acquisition-over-price-dispute","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55513","title":{"rendered":"Merck Abandons $32\u202fBillion Revolution Medicines Acquisition Over Price Dispute"},"content":{"rendered":"\n

Merck &\u202fCo. Inc.<\/strong> (MSD, NYSE:\u202fMRK<\/a>) has reportedly ended acquisition talks<\/strong> with Revolution Medicines<\/strong> after the parties failed to agree on valuation terms, according to the Wall Street Journal. The deal, previously valued between USD\u202f28\u202fbillion and USD\u202f32\u202fbillion<\/strong>, would have given Merck access to daraxonrasib<\/strong>, a late\u2011stage cancer therapy with FDA Fast Track designation<\/strong>.<\/p>\n\n\n\n

Deal Status<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Merck &\u202fCo. Inc. (NYSE:\u202fMRK)<\/td><\/tr>
Target<\/strong><\/td>Revolution Medicines<\/td><\/tr>
Deal Value<\/strong><\/td>USD\u202f28\u202fbillion \u2013 USD\u202f32\u202fbillion (previously discussed)<\/td><\/tr>
Status<\/strong><\/td>Terminated<\/strong> \u2013 unable to agree on terms\/price<\/td><\/tr>
Key Asset<\/strong><\/td>Daraxonrasib (investigational RAS inhibitor)<\/td><\/tr>
Clinical Stage<\/strong><\/td>Late\u2011stage trials<\/td><\/tr>
Regulatory Status<\/strong><\/td>FDA Fast Track designation<\/td><\/tr>
Reported By<\/strong><\/td>Wall Street Journal<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context<\/h2>\n\n\n\n